Adrenocortical carcinoma · NCT00568139
Evaluation of Side Effects of Mitotane
Evaluierung Von Nebenwirkungen Einer Therapie Mit Mitotane Beim Nebennierenkarzinom- Evaluation of Side Effects of Mitotane in Adrenocortical Carcinoma
- Status
- ACTIVE_NOT_RECRUITING (ClinicalTrials.gov)
- Phase
- observational
- Sponsor
- University of Wuerzburg
- Registry records
- CTGOV NCT00568139 (ACTIVE_NOT_RECRUITING)Registry last updated 2026-05-07
Eligibility, line by line
| Verdict | In plain words (machine summary) | Registry text, verbatim | If unmet |
|---|---|---|---|
| inclusion inclusion · condition · confidence 0.97 | Adrenocortical carcinoma | "Adrenocortical carcinoma" | |
| inclusion inclusion · prior therapy · confidence 0.93 | Treatment with mitotane monotherapy as first-line therapy (in adjuvant setting or advanced disease) | "Treatment with mitotane monotherapy as first-line therapy (in adjuvant setting or advanced disease)" |
Criteria extracted by claude-sonnet-5-5; 0 extracted quotes rejected for not matching the registry text.
Full eligibility text as the registry publishes it
Inclusion Criteria: * Adrenocortical carcinoma * Treatment with mitotane monotherapy as first-line therapy (in adjuvant setting or advanced disease)
Routes in: how this trial is reached and paid for
Free patient navigation
myTomorrows (Amsterdam) provides medically trained, multilingual patient navigators who search ClinicalTrials.gov, EU CTIS and ISRCTN and can support a doctor through an expanded-access application. Free to patients and families.
A navigator keeps searching after any single page stops being current. Use it alongside this site, not instead of your oncologist.
Verify with: myTomorrows for patients
0
Sites (1)
Germany
- University Hospital, Würzburg